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Abstract
 
While it is well established that people with non–insulin de-
pendent diabetes mellitus have defects in both insulin secre-
tion and action, the relative contribution of each to glucose
intolerance is not known. Therefore, nondiabetic (lean and
obese) and non–insulin dependent diabetes mellitus subjects
were studied on two occasions. On each occasion, insulin se-
cretion was inhibited with somatostatin and glucose was in-
fused in a pattern and amount that mimicked the systemic
delivery rate normally observed after ingestion of 50 g of
glucose. Insulin also was infused so as to mimic postpran-
dial insulin profiles observed in separate groups of diabetic
and nondiabetic subjects after food ingestion. Glucose turn-
over was measured using the isotope dilution method. A de-
layed pattern of insulin delivery (i.e., a “diabetic” insulin
profile) led to higher (
 
P
 
 
 
,
 
 0.05) glucose concentrations in all
groups; however, the effects were transient, resulting in only
a modest increase in the integrated glycemic responses. An
isolated defect in insulin action had little effect on peak glu-
cose concentration; however, it prolonged the duration of
hyperglycemia, leading to a 2.5–4.2-fold increase (
 
P
 
 
 
,
 
 0.05)
in the integrated glycemic response. A combined defect in
the pattern of insulin secretion and action was additive
rather than synergistic. Both defects caused hyperglycemia
by altering suppression of endogenous glucose release and
stimulation of glucose disposal. Whereas obese diabetic and
nondiabetic subjects had comparable defects in glucose
clearance, non–insulin dependent diabetes mellitus subjects
also had defects in hepatic insulin action. Thus, abnormali-
ties in the pattern of insulin secretion and action alone or in
combination impair glucose tolerance. An isolated defect in
insulin action has a more pronounced and prolonged effect
than does an isolated change in the pattern of insulin secre-
tion. Hepatic and extrahepatic insulin resistance results in
marked and sustained hyperglycemia. (
 
J. Clin. Invest.
 
 1996.
97:2351–2361.) Key words: obesity 
 
•
 
 non–insulin dependent
diabetes mellitus 
 
•
 
 postprandial 
 
• 
 
endogenous glucose re-
lease 
 
•
 
 glucose utilization
 
Introduction
 
Glucose concentrations in nondiabetic individuals rarely ex-
ceed 140–150 mg/dl following food ingestion (1–9). This is be-
cause even a slight increase in glucose produces a prompt in-
crease in insulin (1–9). The coordinated rise in insulin and
glucose suppresses endogenous glucose release and stimulates
glucose uptake which, in turn, minimizes any further rise in
glucose concentration (4–9). In contrast, carbohydrate inges-
tion results in marked and sustained hyperglycemia in people
with diabetes (1–9). There are several possible reasons why
this may occur. Insulin secretion is both decreased and delayed
in non–insulin dependent diabetes mellitus (NIDDM)
 
1
 
 (1–9).
Furthermore, people with NIDDM are resistant to insulin
(10–14).
Numerous studies have demonstrated that either of these
abnormalities have the potential to alter glucose tolerance
(1–14). However, the relative contribution of each to abnor-
mal postprandial glucose metabolism in NIDDM has not been
established. In particular, it is not currently known whether de-
fects in insulin secretion and insulin action result in the same
pattern and degree of hyperglycemia, nor is it known whether
the two together cause a greater impairment in carbohydrate
tolerance than either alone. Such an outcome is not inevitable
since hyperglycemia per se, by promoting glucose uptake and
inhibiting glucose release (15–20), could compensate in part or
in whole for a decrease in the pattern of insulin secretion or ac-
tion. Novel therapies that improve insulin action or that re-
store the pattern and amount of circulating insulin to concen-
trations observed in nondiabetic subjects are in the process of
being developed (21–23). Therefore, the answers to the above
questions are of practical as well as physiologic interest.
In the present experiments, we sought to determine the rel-
ative contribution of defects in insulin secretion and action to
postprandial carbohydrate tolerance. To do so, we first charac-
terized the postprandial insulin profile observed in a typical
group of people with NIDDM after eating a standard mixed
meal. We then used a computer driven infusion system to de-
liver insulin so as to reproduce this “diabetic” profile as well as
a “nondiabetic” insulin profile previously observed in healthy
lean nondiabetic subjects (24). Endogenous insulin secretion
was inhibited with somatostatin on both occasions. Glucose
also was infused so as to mimic the amount and pattern of glu-
cose that normally enters the systemic circulation following in-
gestion of 50 g of carbohydrate (4, 6, 8). This experimental de-
sign enabled us to ascertain the effects of (
 
a
 
) changes in insulin
action by comparing the glycemic responses observed in the
lean vs obese vs NIDDM subjects during a nondiabetic insulin
profile, (
 
b
 
) changes in the pattern of insulin secretion by com-
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paring the glycemic responses observed during the nondiabetic
and diabetic insulin profiles in each of the three groups, and
(
 
c
 
) changes in both the pattern of insulin secretion and action
by comparing the glycemic responses observed during the dia-
betic insulin profile in the two insulin-resistant groups to those
observed during the nondiabetic insulin profile in the lean in-
sulin-sensitive subjects. Measurement of glucose turnover also
enabled us to determine the relative contribution of changes in
the pattern and rates of endogenous glucose release and dis-
posal to the alterations in glucose tolerance.
 
Methods
 
Subjects. 
 
After approval from the Mayo Institutional Review Board,
7 lean nondiabetic, 13 obese nondiabetic, and 14 obese subjects with
NIDDM gave informed written consent to participate in the study.
Seven of the diabetic and six of the obese nondiabetic subjects partic-
ipated in the mixed meal study in which the postprandial diabetic in-
sulin profile was defined. The remainder of the subjects participated
in the prandial glucose and insulin infusion studies in which the ef-
fects of alterations in the pattern of insulin delivery in the presence of
differing degrees of insulin resistance were examined. The character-
istics of the subjects are shown in Table I. Age and gender did not dif-
fer either between or within groups in the two studies. Body-mass in-
dex in the NIDDM and obese nondiabetic subjects also did not differ
either between or within groups. However, the percent body fat was
slightly lower (
 
P
 
 
 
,
 
 0.05) in the NIDDM than the obese nondiabetic
subjects. By design, the lean nondiabetic subjects had a lower body-
mass index and a lower percentage of body fat than did the two obese
groups. The mean glycosylated hemoglobin concentrations (GlycAf-
fin; Isolab Inc., Akron, OH; normal range 4–7%) did not differ in the
NIDDM subjects in the mixed meal and the prandial glucose and in-
sulin infusion studies (10.0
 
6
 
1.0 vs 9.5
 
6
 
1%). At the time of screening,
three of the diabetic subjects in the mixed meal studies and six in the
prandial glucose and insulin infusion studies were taking sulpho-
nylureas. These agents were discontinued at least 48 h before study.
One diabetic subject in the mixed meal study was taking intermedi-
ate-acting insulin, which was discontinued 36 h before the study. All
subjects were in good health, had normal blood pressure, and were at
stable weight. None regularly engaged in vigorous exercise or took
any medication other than sulfonylureas. The nondiabetic subjects
did not have a history of diabetes in their first-degree relatives.
 
Experimental design. 
 
For the mixed meal studies, subjects were
admitted to the General Clinical Research Center at 1700 hours on
the evening before the study. A standard 10-cal/kg meal (50% carbo-
hydrate, 15% protein, and 35% fat) was eaten between 1730 and 1800
hours after which subjects were fasted. At 
 
z
 
 0600 the next morning,
an 18-gauge catheter was inserted retrogradely into a hand vein and
this hand was placed in a heated Plexiglas box and maintained at a
temperature of 
 
z
 
 55
 
8
 
C to allow sampling of arterialized blood. At
0800, subjects ingested a mixed meal (472 kcal; 45% carbohydrate as
50 g of glucose contained in jello, and 40% fat and 15% protein as
scrambled eggs). Blood was sampled at regular intervals before and
after the meals to permit measurement of glucose and insulin concen-
trations.
For the prandial glucose and insulin infusion studies, subjects
were admitted to the General Clinical Research Center the evening
before study and an 18-gauge catheter was inserted into a forearm
vein. After ingestion of a standard evening meal, the nondiabetic sub-
jects were infused overnight with 0.9% saline; whereas, the diabetic
subjects were infused with insulin. The insulin infusion was adjusted
to maintain plasma glucose concentrations during the night at 
 
z
 
 5
mM in the diabetic subjects (20, 25, 26). On the following morning, an
additional cannula was inserted retrogradely into a dorsum hand vein
at 0600. The hand was then placed in a heated Plexiglas box as in the
mixed meal study and maintained at a temperature of 
 
z
 
 55
 
8
 
C to al-
low sampling of arterialized venous blood.
Primed-continuous infusions of [
 
14
 
CO
 
2
 
]bicarbonate (110 
 
m
 
Ci
prime, 1.1 
 
m
 
Ci/min continuous) and [6-
 
3
 
H]glucose (17 
 
m
 
Ci prime, 0.17
(Ci/min continuous) were started at 0700 (
 
2
 
180 min) and 0800 (
 
2
 
120
min) hours, respectively, and continued until the end of the study. At
1000 (time zero), an infusion of somatostatin (60 ng/kg/per min) was
started in all groups in order to inhibit endogenous hormone secre-
tion. Growth hormone (3 ng/kg/per min), and glucagon (0.65 ng/kg/
per min for the first 2 h and 1.3 ng/kg/per min thereafter) also were
infused to replace basal levels. On one occasion, insulin was infused
in a manner designed to produce a nondiabetic postprandial insulin
profile, mimicking that previously observed in lean nondiabetic sub-
jects after glucose ingestion (24). On the other occasion, it was in-
fused to produce a diabetic profile, mimicking the plasma insulin con-
centration observed in the diabetic subjects in the mixed meal study.
The insulin infusion rates to produce the nondiabetic and diabetic
profiles are given in Table II. The order of study was random. The di-
abetic profile used the identical amount of insulin as the nondiabetic
profile, with the insulin infusion program being modified to create a
lower peak at a later time (i.e., 120 min).
Glucose was infused as previously described (20) in an amount
(
 
z
 
 35 g) and pattern that mimicked the systemic rate of delivery of
glucose that normally occurs following ingestion of 50 g of glucose (4,
6, 8). To avoid the confounding effects introduced by counter regula-
tion, the study was terminated when the glucose concentration fell
below 4.3 mmol/liter, at which time the intravenous infusions were
discontinued and subjects were given glucose. In these instances, data
generated thereafter (i.e., the last 2–3 time points) were excluded
from analysis. Glucose levels fell below 4.3 mmol/liter during both
the nondiabetic and diabetic insulin profiles in four of the seven lean
nondiabetic subjects. In contrast, glucose levels fell to below 4.3
mmol/liter in only one of the obese subjects during the diabetic pro-
file and in none of the NIDDM subjects during either profile.
All infused glucose contained [6-
 
3
 
H]glucose. The basal infusion of
[6-
 
3
 
H]glucose was varied to approximate the anticipated pattern of
change of endogenous glucose release (20). By so doing, the mean
 
Table I. Characteristics of the Study Groups
 
Mixed meal study Insulin infusion studies
Obese
nondiabetic NIDDM
Lean
nondiabetic
Obese
nondiabetic NIDDM
 
Age (yr) 50
 
6
 
3 53
 
6
 
3 50
 
6
 
3 50
 
6
 
4 57
 
6
 
3
Gender (M/F) 4/2 4/3 4/3 3/4 5/2
Body mass index* 28
 
6
 
2 31
 
6
 
2 22
 
6
 
1 34
 
6
 
2 31
 
6
 
1
Percentage of body fat — — 26
 
6
 
3 44
 
6
 
3 32
 
6
 
3
*Weight in kilograms divided by square of height, in meters.
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plasma glucose–specific activity was maintained within 5% of basal
values throughout the study in all groups. Breath was collected for
measurement of 
 
14
 
CO
 
2
 
 specific activity as previously described (6).
Subjects were requested to void just before and at the end of the
study to enable measurement of urine glucose excretion.
 
Analytical technique. 
 
Arterialized plasma samples were placed
in ice, centrifuged at 4
 
8
 
C, separated, and stored at 
 
2
 
20
 
8
 
C until assay.
C-peptide and glucagon concentrations were measured using re-
agents purchased from Linco Research Inc. (St. Louis, MO). Growth
hormone was measured using reagents purchased from ICN Bio-
chemicals Inc. (Costa Mesa, CA). Glucose-specific activity was mea-
sured as previously described (4). Lean body mass and percentage of
body fat were determined by dual-energy x-ray absorptiometry (DPX
scanner; Lunar Corporation, Madison, WI). Glucose concentrations
were measured using a glucose analyzer (Yellow Springs Instrument
Co., Yellow Springs, OH).
 
Calculation of glucose turnover.  
 
Glucose-specific activity was smoothed
using the OOPSEG program of Bradley et al. (27). Glucose appear-
ance and disappearance were calculated using the equations of Steele
et al. (28). Glucose clearance was calculated by dividing glucose dis-
appearance by glucose concentration. Endogenous glucose release
was determined by subtracting the glucose infusion rate from the
tracer-determined rate of glucose appearance. The percentage of glu-
cose derived from 
 
14
 
CO
 
2
 
 was calculated by dividing the plasma
[
 
14
 
C]glucose–specific activity by breath 
 
14
 
CO
 
2
 
–specific activity (6).
Rates of glucose disappearance and clearance are expressed per kilo-
gram lean body wt.
 
Statistical analysis. 
 
Data in the text and figures are expressed as
mean
 
6
 
SEM. Integrated responses and responses above basal were
calculated using the trapezoidal rule. Integrated response was defined
as total area above zero during the insulin infusions. Area above
basal was defined as the area above the mean of values present dur-
ing the 30 min before the insulin infusions. Paired tests were used to
compare results within groups (i.e., nondiabetic vs diabetic profiles).
Analysis of variance was used to compare results among groups (lean
vs obese vs NIDDM subjects) followed by nonpaired tests if signifi-
cance was observed. Comparisons were made using either Student’s
or Windsorized 
 
t
 
 tests (29). One-tailed tests were used to test the hy-
pothesis that a decrease in the pattern of insulin secretion or action
resulted in higher blood and urinary glucose concentrations, lower
disposal, and greater endogenous glucose release. All other tests
were two tailed. A 
 
P
 
 
 
,
 
 0.05 was considered statistically significant.
 
Results
 
Glucose and insulin concentrations following mixed meal inges-
tion.
 
Plasma glucose concentrations were higher (
 
P
 
 
 
,
 
 0.01) in
the obese NIDDM than in the obese nondiabetic subjects both
before (10.2
 
6
 
1.0 vs 5.0
 
6
 
0.1 mmol/liter) and after (3.9
 
6
 
0.3 vs
1.8
 
6
 
0.1 mmol/liter per 5 h) meal ingestion (Fig. 1). Plasma glu-
cose concentrations peaked in the nondiabetic subjects at 
 
z
 
 9.0
mmol/liter at 60 min, returning to basal values by 
 
z
 
 120 min.
Preprandial insulin concentrations did not differ between
groups. Insulin concentrations during the first 2 h after meal
ingestion were lower (
 
P
 
 
 
,
 
 0.01) in the diabetic than nondia-
betic subjects (7.8
 
6
 
3.1 vs 32.5
 
6
 
7.8 nmol/liter per 2 h). Insulin
concentrations did not differ between groups thereafter.
 
C-peptide, glucagon, and growth hormone concentrations
during prandial glucose and insulin infusions.
 
Somatostatin was
infused to ensure that endogenous hormone secretion was in-
hibited in all groups. C-peptide concentrations at time zero
(i.e., before the start of the somatostatin infusion) differed
among groups (
 
P
 
 
 
,
 
 0.01) being highest in the obese nondia-
betic subjects, next highest in the lean nondiabetic subjects,
and lowest in the obese NIDDM subjects (Fig. 2). Somatosta-
tin promptly inhibited insulin secretion in all groups, resulting
in C-peptide concentrations that did not differ in any of the
three groups during either the nondiabetic or diabetic insulin
profiles. Glucagon and growth hormone concentrations also
did not differ among the three groups during the somatostatin/
replacement hormone infusions on either study day.
 
Table II. Insulin Infusion Rates
 
Milliunits per kilogram lean body mass per min
Time (min)
 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
 
Nondiabetic profile 0.391 0.735 1.009 0.902 0.753 0.665 0.652 0.608 0.444 0.571 0.491 0.346 0.346 0.346 0.346
Diabetic profile 0.325 0.351 0.379 0.377 0.436 0.47 0.494 0.508 0.521 0.529 0.532 0.533 0.527 0.516 0.507
 
Milliunits per kilogram lean body mass per min
 
150 160 170 180 190 200 210 220 230 240 250 260 270 280
 
Nondiabetic profile 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346 0.346
Diabetic profile 0.499 0.487 0.476 0.468 0.454 0.444 0.434 0.423 0.411 0.4 0.387 0.375 0.363 0.352
Figure 1. Glucose and insulin concentrations observed in obese 
NIDDM and nondiabetic subjects following ingestion of a mixed 
meal at time zero.
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Effects of differences in insulin action on glucose tolerance
Glucose and insulin concentrations in lean, obese, and NIDDM
subjects.
 
Glucose concentrations in the lean nondiabetic sub-
jects increased to a peak of 
 
z
 
 9 mmol at 40–50 min and re-
turned to basal values by 
 
z
 
 120 min during the nondiabetic in-
sulin profile (Fig. 3, top left). This pattern was virtually
superimposable on that observed in the nondiabetic subjects
after meal ingestion (see Fig. 1, top), indicating that the pran-
dial glucose infusion and the nondiabetic insulin profile mod-
eled from previous data were sufficiently well matched to re-
sult in near normal glucose tolerance.
The NIDDM subjects were infused with insulin during the
night so that glucose concentrations would be equal in all
groups at the start of the study. This resulted in higher (
 
P
 
 
 
,
 
0.05) basal insulin in the NIDDM subjects on both study days
(156
 
6
 
75, and 156
 
6
 
61 pmol/liter), than those observed in the
obese nondiabetic subjects (58
 
6
 
8, and 59
 
6
 
10 pmol/liter) and
which in turn were higher than those observed in the lean non-
diabetic subjects (33
 
6
 
4, and 34
 
6
 
3 pmol/liter) consistent with
varying degrees of insulin resistance (Fig. 3, right). Insulin con-
centrations observed during the diabetic insulin profile closely
mimicked those observed in the NIDDM subjects following
meal ingestion (see Fig. 1, bottom).
We anticipated that insulin action would differ among the
three groups. This was confirmed by demonstrating that de-
spite infusion of identical amounts of insulin and glucose, the
Figure 2. C-peptide (left), glucagon (middle), and growth hormone (right) concentrations observed in the lean nondiabetic, obese nondiabetic, 
and subjects with NIDDM during the nondiabetic and diabetic insulin profiles. An infusion of somatostatin, glucagon, and growth hormone was 
started at time zero.
Figure 3. Glucose (left) and insulin (right) concentrations observed in the lean nondiabetic, obese nondiabetic, and NIDDM subjects during the 
nondiabetic and diabetic insulin profiles.
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glycemic response differed (
 
P
 
 
 
,
 
 0.01) amongst groups (Fig. 3,
left). The glucose area above basal was greater (
 
P
 
 
 
,
 
 0.02) in
the NIDDM than in the obese nondiabetic subjects which in
turn was greater (
 
P
 
 
 
,
 
 0.02) than in the lean nondiabetic sub-
jects during both the nondiabetic and diabetic insulin profiles,
respectively (Table III). These differences were primarily due
to a more prolonged elevation of glucose concentration above
basal levels in the NIDDM and obese nondiabetic subjects.
Peak glucose concentrations did not differ among groups dur-
ing the nondiabetic insulin profile. However, peak glucose
concentrations during the diabetic profile tended to be higher
(
 
P
 
 
 
5
 
 0.04–0.06) in the NIDDM subjects (13.0
 
6
 
1.0 mmol/liter)
than those observed in either the lean (10.6
 
6
 
0.4 mmol/liter) or
obese (11.0
 
6
 
0 mmol/liter) nondiabetic subjects.
 
Glucose turnover in lean, obese, and NIDDM subjects.
 
To determine the mechanism by which different degrees of in-
sulin action led to different degrees of glucose tolerance, rates
of glucose disappearance and endogenous glucose release
were measured. Basal rates of endogenous glucose release dif-
fered (
 
P
 
 
 
,
 
 0.02) among groups on both study days (Fig. 4, top
left). In each instance, basal endogenous glucose release was
higher (
 
P , 0.01) in the NIDDM than in the lean subjects. De-
spite the fact that basal insulin concentrations were two- to
threefold higher in the NIDDM than obese nondiabetic sub-
jects, basal endogenous glucose release did not differ between
groups. Integrated endogenous glucose release was greater
(P , 0.01) in the NIDDM subjects than in the obese subjects
during both the nondiabetic and diabetic insulin profiles. Inte-
grated endogenous glucose release was slightly, but signifi-
cantly, (P , 0.05) higher in the obese than lean nondiabetic
subjects. The rate of incorporation of carbon dioxide into glu-
cose showed a similar pattern with the integrated response be-
ing greater (P , 0.01) in the NIDDM than obese subjects on
both study days (Fig. 4, bottom left).
Glucose disappearance did not differ among groups either
before or during the nondiabetic or diabetic insulin profiles
(Fig. 4, top right). However, the rates of disappearance were
not appropriate for the higher prevailing glucose concentra-
tions in either the obese or NIDDM subjects. This was evident
Table III
Glucose area above basal
millimoles per minute
Nondiabetic insulin
profile
Diabetic insulin
profile
Lean 361684* 585670
Obese 9156113‡§ 10616136‡
NIDDM 12406237‡i 15096176‡
*P , 0.01 vs diabetic insulin profile.
‡P , 0.05 vs lean.
§P , 0.05 vs diabetic insulin profile.
iP , 0.06 vs diabetic insulin profile.
Figure 4. Rates of endogenous glucose release (top left), incorporation of carbon dioxide into glucose (bottom left), glucose disappearance (top 
right), and glucose clearance (bottom right) observed in lean nondiabetic, obese nondiabetic, and subjects with NIDDM during the nondiabetic 
and diabetic insulin profiles.
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from the fact that glucose clearance was lower (P , 0.05) dur-
ing both insulin profiles compared to that observed in the lean
nondiabetic subjects (Fig. 4, bottom right). Glucose clearance
did not differ in the obese and NIDDM subjects whether cal-
culated before or after correction for urinary glucose losses.
However, a greater (P , 0.05) portion of glucose disappear-
ance was accounted for by urinary glucose excretion in the
NIDDM than by obese subjects during both the nondiabetic
(3466185 vs 1165 mmol/kg per 5 h) and diabetic (4056154 vs
2168 mmol/kg per 5 h) insulin profiles.
Effects of alterations in the pattern of insulin secretion on 
glucose tolerance
Glucose and insulin concentrations during the nondiabetic and
diabetic insulin profiles. To determine the effects of differences
in the pattern of insulin secretion on glucose tolerance in indi-
viduals with varying degrees of insulin resistance, results ob-
served in the lean nondiabetic, obese nondiabetic, and obese
NIDDM subjects during the nondiabetic insulin profile were
compared to those observed in the same individuals when they
received an identical amount of insulin in the form of a dia-
betic insulin profile.
Basal insulin concentrations were the same on both study
days in all groups (Fig. 5). The diabetic and nondiabetic insulin
profiles produced a pattern of change in insulin concentrations
in all three groups that closely mimicked those observed after
mixed meal ingestion (compare Fig. 5 to Fig. 1). The nondia-
betic insulin profile resulted in a more rapid increase in plasma
insulin concentrations than did the diabetic insulin profile in
all groups (Fig. 5, right). Insulin concentrations were greater
(P , 0.02) during the first 2 h of the nondiabetic than the dia-
betic insulin profiles in all groups. On the other hand, since
identical amounts of insulin were infused in all subjects, inte-
grated insulin concentrations over the 5 h of study did not dif-
fer during the diabetic and nondiabetic profiles in any group.
Basal glucose concentrations were the same on both study
days in all three groups. During the first 2 h of the prandial glu-
cose infusion, plasma glucose concentration rose more (Fig. 5,
left) in the presence of the diabetic than nondiabetic insulin
profile, resulting in a higher (P , 0.02) peak in the lean nondi-
abetic (10.660.4 vs 9.060.2 pmol/liter) and obese nondiabetic
(11.160.4 vs 9.860.4 pmol/liter) subjects as well as in the peo-
ple with NIDDM (12.960.9 vs 10.960.7 pmol/liter). The differ-
ence in glucose concentrations, however, was only transient since
glucose concentrations by the end of the diabetic insulin profile
no longer differed from those observed during the nondiabetic
profile. The net effect of these changes was that the integrated
glycemic response above basal over the entire 5 h of study was
only slightly greater during the diabetic than the nondiabetic
profile (Fig. 4), with the difference reaching statistical significance
(P , 0.01) in the lean subjects and being of borderline signifi-
cance in the obese nondiabetic (P 5 0.05) and NIDDM (P 5 0.06)
subjects. Of interest, the difference between the integrated gly-
cemic response observed during the nondiabetic and diabetic
insulin profiles did not differ in the lean, obese, and NIDDM
groups (diabetic minus nondiabetic areas in Table III).
Glucose turnover during the nondiabetic and diabetic insu-
lin profiles. The nondiabetic and diabetic insulin profiles in-
Figure 5. Glucose (left) and insulin (right) concentrations observed in lean nondiabetic, obese nondiabetic, and subjects with NIDDM. A pran-
dial glucose infusion was started at time zero and insulin was administered so as to reproduce a nondiabetic or diabetic insulin profile.
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hibited endogenous glucose release in all groups (Fig. 6, left).
The pattern of change in endogenous glucose release mirrored
that of insulin; endogenous glucose release fell as insulin con-
centrations rose and rose as insulin concentrations fell. The
more rapid increase in insulin during the nondiabetic than dia-
betic insulin profile resulted in more rapid (P , 0.05) suppres-
sion of both endogenous glucose release and the rate of incor-
poration of carbon dioxide into glucose (an index of
gluconeogenesis) in the lean nondiabetic subjects during the
first 2 h of study, with rates merging thereafter (Fig. 6). Sup-
Figure 6. Rates of endogenous glucose release (left) and incorporation of carbon dioxide into glucose (right) observed in lean nondiabetic, obese 
nondiabetic, and subjects with NIDDM during the nondiabetic and diabetic insulin profiles.
Figure 7. Rates of glucose disappearance (left) and glucose clearance (right) observed in lean nondiabetic, obese nondiabetic, and subjects with 
NIDDM during the nondiabetic and diabetic insulin profiles.
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pression also tended to be more rapid during the nondiabetic
than the diabetic insulin profiles in the other two groups; how-
ever, the variation was greater and the differences were not
statistically significant.
Glucose disappearance increased to a similar extent in all
groups (Fig. 7, left). However, disposal was not appropriate for
the higher prevailing glucose concentrations in either of the
nondiabetic groups since glucose clearance over the first 2 h of
study was lower (P , 0.05) during the diabetic than nondia-
betic insulin profile (Fig. 7, right). A similar, but statistically
nonsignificant pattern was observed in the NIDDM subjects.
As with endogenous glucose release, differences in clearance
were only evident during the first 2 h when the differences in
insulin concentrations were the greatest.
Discussion
While it is well established that people with NIDDM have de-
fects in both insulin secretion and action (1–14), the relative
contribution of each to altered glucose tolerance remains un-
clear. Under conditions of daily living, a change in insulin ac-
tion results in a change in glucose concentration which in turn
causes a change in insulin secretion. Methods such as euglyce-
mic and hyperglycemic clamps circumvent this feedback loop
by assessing insulin action and/or insulin secretion in the pres-
ence of fixed, constant glucose concentrations. While these ap-
proaches allow measurement of the severity of defects in se-
cretion and action, they do not permit determination of the
impact of these defects on glucose tolerance. This is not a triv-
ial problem since hyperglycemia can compensate for insulin
lack and the rate change of glucose production and utilization
in response to a change in insulin may be more important than
the steady state response assessed by traditional glucose
clamps. Therefore, isolated alterations in the pattern of insulin
secretion and action may have different qualitative as well as
quantitative effects on glucose tolerance. Furthermore, defects
in both may be synergistic or additive.
The present studies sought to address these questions by
using an experimental paradigm that evaluated the impact of
defects in the pattern of insulin secretion or action by creating
nondiabetic and diabetic insulin profiles in individuals who
had differing degrees of insulin resistance, namely, lean nondi-
abetic, obese nondiabetic, and obese NIDDM subjects. Al-
though insulin secretion varies from individual to individual,
the pattern of change in postprandial insulin concentrations is
remarkably consistent by the time frank hyperglycemia devel-
ops (1–9). In the present studies, we fed a group of individuals
with NIDDM a standard mixed meal, and then used the ob-
served insulin concentrations to create a typical diabetic insu-
lin profile. The temporal pattern of this profile, namely, a
blunted and delayed peak with a total integrated response that
did not differ from that in nondiabetic subjects fed the same
meal, is virtually identical to that which we and other investi-
gators have observed in other NIDDM subjects following food
ingestion (1–9). Thus, while there is no such thing as a single
postprandial diabetic insulin profile, the one employed in the
present experiments closely mimics that observed in a large
number of people with NIDDM.
Previous studies have established the importance of the
timing of insulin secretion on glucose tolerance (30–34). Con-
sistent with the present results, those studies demonstrated
that, for any given glucose challenge, a delay in insulin delivery
results in a greater increment in plasma glucose concentration
(30–34). The present experiments extend those studies by ex-
amining the effects of alterations in the pattern of insulin se-
cretion in the presence and absence of insulin resistance under
conditions simulating those observed after eating. Each sub-
ject received z 35 g of glucose, mimicking the amount of glu-
cose that normally enters the systemic circulation after inges-
tion of 50 g of carbohydrate (4, 6, 8). Each subject also was
infused with insulin. When given so as to reproduce a nondia-
betic profile, it was sufficient to result in glucose concentra-
tions in lean insulin-sensitive individuals that were virtually su-
perimposable upon those observed in the nondiabetic subjects
following ingestion of 50 g of carbohydrate. Administration of
an identical amount of insulin to the lean nondiabetic subjects
as a diabetic insulin profile, resulted in an z 1.5 mmol/liter
(z 25 mg/dl) greater increment in glucose concentration.
However, glucose concentrations rapidly fell back to levels
present during the nondiabetic profile. Despite wide differ-
ences in insulin action (see below), the pattern was essentially
the same in all three groups. These data indicate that an iso-
lated defect in the pattern of insulin secretion of a magnitude
typically observed in most frankly hyperglycemic NIDDM
subjects in itself causes only modest and transient hyperglyce-
mia in lean nondiabetic individuals.
Inspection of the glucose turnover data provides insight as
to why the differences in glucose concentrations during the
nondiabetic and diabetic insulin profiles were not sustained.
Both insulin and glucose interact to regulate glucose produc-
tion and disposal (14–20). An increase in either glucose or in-
sulin suppresses endogenous glucose release and stimulates
glucose uptake; a concurrent rise in both glucose and insulin
exerts a greater effect than a rise in either alone. The more
rapid increase in insulin during the first portion of the nondia-
betic insulin profile resulted in a more rapid suppression of en-
dogenous glucose release. The concomitant decrease in the
rate of incorporation of carbon dioxide into glucose suggests
that the fall in endogenous glucose release was, at least in part,
due to inhibition of gluconeogenesis (6, 33, 34). Differences
were most evident in the lean subjects. However, the pattern
of production and disposal changed with time; glucose concen-
trations were higher during the diabetic insulin profile from 1 h
onward. This further suppressed glucose release and further
increased glucose disappearance. Although rates of disappear-
ance were not appropriate for the prevailing glucose concen-
tration (i.e., glucose clearance was decreased), the net effect of
these changes was the return of glucose concentrations to lev-
els observed during the nondiabetic profile. Thus, the higher
late glucose and insulin concentrations present during the dia-
betic profile compensated for the early delay in the pattern of
insulin secretion, thereby minimizing the overall effect on glu-
cose tolerance. It is important to point out, however, that the
present experiments only studied the effect of an alteration in
the timing of insulin delivery since the amounts of insulin in-
fused were identical on both occasions. A combined delay and
reduction in insulin response is likely to cause more marked
hyperglycemia than either one alone.
Since all subjects were given identical amounts of insulin
and glucose, the glycemic excursion was determined by the in-
teraction between insulin action and glucose effectiveness (de-
fined as the ability of glucose to stimulate its own uptake and
to suppress its own release). We have previously demonstrated
in a separate set of experiments that glucose effectiveness in
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presence of the same nondiabetic insulin profile does not differ
in NIDDM and nondiabetic subjects (20). Therefore, the
greater rise in glucose concentrations in the NIDDM subjects
during the nondiabetic insulin profile was solely caused by in-
sulin resistance. We are unaware of any studies comparing glu-
cose effectiveness in lean and obese nondiabetic subjects in the
presence of the glucose and insulin concentrations resembling
those present in the current experiments. If glucose effective-
ness is impaired by obesity per se, then the higher glucose con-
centrations observed in the obese than in the lean nondiabetic
subjects may have been caused in part by factors other than in-
sulin resistance.
A defect in insulin action had a different temporal effect on
glucose tolerance than did a decrease in the pattern of insulin
secretion. A decrease in insulin action only minimally influ-
enced peak glucose concentration, but markedly prolonged
the duration of hyperglycemia. A decrease in insulin action to
a level observed in people with NIDDM had a much greater
impact on glucose tolerance than did a decrease in the pattern
of insulin secretion. Whereas a decrease early in the pattern of
insulin secretion led to only a slight increase in the glucose
area above basal (compare glucose areas during nondiabetic
and diabetic profiles in Table III), a decrease in insulin action
to a level caused by obesity alone led to a 2.5-fold increase in
the glucose area above basal (compare glucose areas during
nondiabetic profiles in lean and obese subjects in Table III).
Even more impressive, a decrease in insulin action to a level
caused by obesity plus NIDDM led to a 4.2-fold greater glyce-
mic excursion (compare glucose areas during nondiabetic pro-
files in lean and NIDDM subjects in Table III). Concurrent de-
fects in the pattern of insulin secretion and action caused a
greater deterioration in glucose tolerance than either alone.
Thus, in contrast to a decrease in the pattern of insulin secre-
tion, insulin resistance caused sustained and marked hypergly-
cemia.
The ability of insulin to suppress endogenous glucose re-
lease and to stimulate glucose disposal differed depending on
the degree of insulin resistance. Whereas hyperglycemia in the
obese nondiabetic subjects was associated with impaired glu-
cose clearance, hyperglycemia in the more insulin-resistant
NIDDM subjects was due to both decreased glucose clearance
and excessive endogenous glucose release. Although the de-
gree of impairment in glucose clearance was similar in the
NIDDM and obese nondiabetic subjects, urinary glucose loss
was greater in the diabetic subjects, implying lower tissue glu-
cose uptake. In addition, glucose concentrations remained es-
sentially flat in the NIDDM subjects during the last few hours
of the study, at which time tissue glucose uptake and renal glu-
cose excretion equaled the (elevated) rate of endogenous glu-
cose release. A similar situation occurred in the obese individ-
uals. However, since endogenous glucose release was lower,
this equilibrium was achieved at lower glucose concentrations,
with urinary glucose excretion making a negligible contribu-
tion. Thus the greater the defect in insulin action, the higher
the glucose concentration had to rise to balance glucose ap-
pearance and disappearance. Of note, as is evident from Fig. 3,
the addition of hepatic insulin resistance to an inappropriately
low rate of glucose disappearance was sufficient to convert the
modestly elevated glucose concentrations in the nondiabetic
obese subjects to frankly diabetic levels (35) in the NIDDM
subjects. This occurred despite the fact that the latter, if any-
thing, had a lower percentage of body fat than the former, im-
plying that factors other than obesity contributed to insulin re-
sistance in the NIDDM subjects (Table I).
Limitations. As with all studies, the present experiments
have limitations. Ideally, insulin should have been infused into
the portal venous system. However, recent experiments have
demonstrated that peripheral infusion of insulin has an equal,
if not greater, effect than does portal infusion (36–38). Since
insulin was infused in the same manner in all subjects, the
route of insulin delivery is unlikely to have influenced our con-
clusions. Endogenous insulin secretion was inhibited and the
same amount of insulin was infused in all subjects. However,
since basal insulin concentrations were higher, insulin concen-
trations during the insulin profiles also tended to be higher in
the NIDDM subjects. This, if anything, would lead to an un-
derestimate of the severity of insulin resistance. We do not
know what the portal glucagon concentrations actually were
during the experiments. However, assuming that portal venous
glucagon concentrations were 40% higher than peripheral glu-
cagon concentrations before somatostatin infusion, but ap-
proximated peripheral glucagon concentrations during soma-
tostatin infusion (39–42), portal glucagon concentrations in all
groups fell from z 140 pg/ml at time zero to z 100 pg/ml from
30 to 120 min, and then rose back to z 140 pg/ml from 120 to
300 min (Fig. 2). This pattern of suppression, which mimics
that observed in nondiabetic subjects after food ingestion,
does not normally occur in people with diabetes mellitus (5–9).
Therefore, defects in insulin secretion and/or action of a mag-
nitude similar to those present in the current experiments may
lead to even greater hyperglycemia when postprandial sup-
pression of glucagon is impaired (43).
Glucose was infused rather than ingested. This approach
was used since somatostatin is a potent inhibitor of gastric
emptying (44), and somatostatin was necessary to ensure that
endogenous insulin secretion was equally inhibited in all
groups. Intravenous infusion of glucose also avoids the uncer-
tainties introduced by variations in intestinal absorption. How-
ever, this precludes assessment of the effects of differences in
insulin secretion/action on first pass splanchnic glucose uptake.
Future studies will be required to address this question. Mea-
surement of the rate of incorporation of carbon dioxide into
glucose provides a qualitative rather than quantitative esti-
mate of gluconeogenesis (6, 45, 46). The limitations of this, as
well as other similar isotopic approaches for the measurement
of gluconeogenesis in vivo, have been previously discussed in
detail (6, 45, 46).
The method used to assess insulin action is a modification
of the so-called insulin suppression test (10, 11). Insulin was
given as a continuously changing infusion not only because this
afforded us the opportunity to compare nondiabetic and insu-
lin diabetic profiles, but also because insulin administered in
this fashion has a greater biologic effect than the identical
amount of insulin given as a constant infusion (47). Glucose
concentrations were maintained in the euglycemic range in the
NIDDM subjects during the night. This was done so that glu-
cose concentrations would begin at the same level in all
groups. If normalization of glucose concentration during the
night improved insulin action in the NIDDM subjects, then we
may have underestimated the impact of insulin resistance in
these subjects. However, this would be a conservative error
since, as it was, the effect of insulin resistance on carbohydrate
tolerance was dramatic.
Conclusions. The present experiments demonstrate that
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an isolated defect in insulin secretion or action of a magnitude
typical of that present in people with NIDDM causes hyper-
glycemia. However, the severity and pattern of hyperglycemia
differs. A delay in insulin secretion is associated with tran-
siently higher peak glucose concentrations, resulting in a mod-
est increase in the integrated glycemic response. In contrast,
defects in insulin action markedly impair glucose tolerance by
prolonging the duration of hyperglycemia. Both cause hyper-
glycemia by altering the pattern and/or rate of change of en-
dogenous glucose release and the efficiency of glucose uptake.
Whereas obese nondiabetic and NIDDM subjects had compa-
rable defects in glucose clearance, the addition of hepatic insu-
lin resistance in the latter converted a glucose profile that was
glucose intolerant according to National Diabetes Data Group
criteria to frank diabetes mellitus (35). If avoidance of hyper-
insulinemia is desirable, these data suggest that agents that en-
hance insulin action are likely to result in a greater improve-
ment in glucose tolerance in people with NIDDM than are
agents that act solely by restoring early postprandial insulin se-
cretion to normal. They also suggest that such agents will need
to increase both hepatic and extrahepatic response to insulin if
postprandial glucose metabolism is to be completely restored
to normal.
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